Partner Eric McClafferty
co-authored the Pharma Horizon
article “Export controls: Little known risks for biopharma companies.” According to the article, recent discussions among pharmaceutical and biotech companies, public sector research scientists and the U.S. Government revealed a significant lack of awareness about the potential applicability of export controls to their activities. Even unintentional failure to comply with restrictions imposed on the transnational movement of certain chemicals, pathogens, toxins, genetic material, and associated equipment or technology can result in penalties and reputational damage. The article introduces the fundamental regulations and illustrates the importance of building export control policies and tools into compliance programs for biopharmaceutical companies.
To read the full article, click here